Annual report pursuant to Section 13 and 15(d)

Income Taxes (Details)

v3.8.0.1
Income Taxes (Details) - USD ($)
Dec. 31, 2017
Dec. 31, 2016
Deferred tax assets:    
Net operating losses carry forward $ 30,826,534 $ 38,874,255
Share-based compensation 3,731,413 8,081,711
Research & Development/Orphan Drug Credits 6,324,998 830,085
Others 11,369 16,329
Less: valuation allowance (40,894,314) (47,802,380)
Deferred tax assets, net $ 0 $ 0